Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

391
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
391
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

590
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
590
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.3K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.3K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

502
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
502
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

964
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
964
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

933
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
933

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study.

The lancet. Gastroenterology & hepatology·2026
Same author

The Challenges of Performing Controlled Trials of Diet Therapies in Gastroenterology.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Efficacy of gut-brain neuromodulators and brain-gut behaviour therapies for irritable bowel syndrome: systematic review and network meta-analysis.

Gut·2026
Same author

Belief of Allocated Treatment and Symptom Response to Amitriptyline in Irritable Bowel Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Recommendations for the Evaluation and Management of Inflammatory Bowel Disease With Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus.

Gastroenterology·2026
Same author

Design of Treatment Trials for Disorders of Gut-Brain Interaction.

Gastroenterology·2026

Related Experiment Video

Updated: Dec 6, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K

Functional dyspepsia.

Alexander C Ford1, Sanjiv Mahadeva2, M Florencia Carbone3

  • 1Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK; Leeds Gastroenterology Institute, St James's University Hospital, Leeds, UK.

Lancet (London, England)
|October 13, 2020
PubMed
Summary
This summary is machine-generated.

Functional dyspepsia, affecting 16% of healthy individuals, involves upper abdominal symptoms without a clear structural cause. Treatment is challenging due to incomplete understanding, but Helicobacter pylori eradication and other therapies show promise.

More Related Videos

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

931

Related Experiment Videos

Last Updated: Dec 6, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.9K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

931

Area of Science:

  • Gastroenterology
  • Functional gastrointestinal disorders

Background:

  • Dyspepsia encompasses upper abdominal symptoms like pain, burning, fullness, and early satiety.
  • Functional dyspepsia (FD) affects up to 16% of the general population and lacks a structural explanation in 80% of cases.
  • Risk factors for FD include psychological issues, H. pylori infection, NSAID use, smoking, and female sex.

Purpose of the Study:

  • To review the current understanding of functional dyspepsia, including its pathophysiology, diagnosis, and management.
  • To highlight the challenges in treating FD due to its complex and incompletely understood mechanisms.

Main Methods:

  • Literature review of functional dyspepsia pathophysiology, risk factors, diagnostic approaches, and therapeutic options.
  • Analysis of current evidence for various treatment modalities, including eradication therapy, acid suppressants, prokinetics, and neuromodulators.

Main Results:

  • The pathophysiology of FD is likely multifactorial, involving gut-brain axis dysfunction, leading to motility issues, visceral hypersensitivity, and altered microbiota.
  • Endoscopy utility is limited in FD, recommended mainly for older patients (>55) or those with alarm features.
  • Several therapies show effectiveness, including H. pylori eradication, PPIs, H2RAs, prokinetics, and central neuromodulators, though the role of psychological therapies is uncertain.

Conclusions:

  • Functional dyspepsia is a chronic condition with fluctuating symptoms, often challenging to treat due to incomplete pathophysiological understanding.
  • H. pylori eradication is recommended for positive patients. Future research may yield disease-modifying therapies.